Population Pharmacokinetic Modeling and Dose Optimization of Acetaminophen and its Metabolites Following Intravenous Infusion in Critically ill Adults.
Journal
European journal of drug metabolism and pharmacokinetics
ISSN: 2107-0180
Titre abrégé: Eur J Drug Metab Pharmacokinet
Pays: France
ID NLM: 7608491
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
accepted:
13
06
2023
medline:
6
9
2023
pubmed:
30
6
2023
entrez:
30
6
2023
Statut:
ppublish
Résumé
Acetaminophen (paracetamol) is a ubiquitously administered drug in critically ill patients. Considering the dearth of literature, we evaluated the population pharmacokinetics of intravenous acetaminophen and its principal metabolites (sulfate and glucuronide) in this population. Critically ill adults receiving intravenous acetaminophen were included in the study. One to three blood samples were withdrawn per patient for the estimation of acetaminophen, and its metabolites (acetaminophen glucuronide and acetaminophen sulfate). High-performance liquid chromatography was used for measuring serum concentrations. We used nonlinear mixed-effect modeling for estimating the primary pharmacokinetic parameters of acetaminophen and its metabolites. The effect of covariates was evaluated followed by dose optimization using Monte Carlo simulation. Patient factors such as demographic information, liver and renal function tests were used as covariates in population pharmacokinetic analysis. The therapeutic range for serum acetaminophen concentration was considered to be 66-132 μM, while 990 μM was considered as the threshold for toxic concentration. Eighty-seven participants were recruited. A joint two-compartment acetaminophen pharmacokinetic model linked to glucuronide and sulfate metabolite compartments was used. The central and peripheral volume distributions were 7.87 and 8.87 L/70 kg, respectively. Estimated clearance (CL) was 0.58 L/h/70 kg, while intercompartmental clearance was 44.2 L/h/70 kg. The glucuronide and sulfate metabolite CL were 22 and 94.7 L/h/70 kg, respectively. Monte Carlo simulation showed that twice-daily administration of acetaminophen would result in a relatively higher proportion of patient population achieving and retaining serum concentrations in the therapeutic range, with reduced risk of concentrations remaining in the toxic range. A joint pharmacokinetic model for intravenous acetaminophen and its principal metabolites in a critically ill patient population has been developed. Acetaminophen CL in this patient population is reduced. We propose a reduction in the frequency of administration to reduce the risk of supra-therapeutic concentrations in this population.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Acetaminophen (paracetamol) is a ubiquitously administered drug in critically ill patients. Considering the dearth of literature, we evaluated the population pharmacokinetics of intravenous acetaminophen and its principal metabolites (sulfate and glucuronide) in this population.
METHODS
METHODS
Critically ill adults receiving intravenous acetaminophen were included in the study. One to three blood samples were withdrawn per patient for the estimation of acetaminophen, and its metabolites (acetaminophen glucuronide and acetaminophen sulfate). High-performance liquid chromatography was used for measuring serum concentrations. We used nonlinear mixed-effect modeling for estimating the primary pharmacokinetic parameters of acetaminophen and its metabolites. The effect of covariates was evaluated followed by dose optimization using Monte Carlo simulation. Patient factors such as demographic information, liver and renal function tests were used as covariates in population pharmacokinetic analysis. The therapeutic range for serum acetaminophen concentration was considered to be 66-132 μM, while 990 μM was considered as the threshold for toxic concentration.
RESULTS
RESULTS
Eighty-seven participants were recruited. A joint two-compartment acetaminophen pharmacokinetic model linked to glucuronide and sulfate metabolite compartments was used. The central and peripheral volume distributions were 7.87 and 8.87 L/70 kg, respectively. Estimated clearance (CL) was 0.58 L/h/70 kg, while intercompartmental clearance was 44.2 L/h/70 kg. The glucuronide and sulfate metabolite CL were 22 and 94.7 L/h/70 kg, respectively. Monte Carlo simulation showed that twice-daily administration of acetaminophen would result in a relatively higher proportion of patient population achieving and retaining serum concentrations in the therapeutic range, with reduced risk of concentrations remaining in the toxic range.
CONCLUSION
CONCLUSIONS
A joint pharmacokinetic model for intravenous acetaminophen and its principal metabolites in a critically ill patient population has been developed. Acetaminophen CL in this patient population is reduced. We propose a reduction in the frequency of administration to reduce the risk of supra-therapeutic concentrations in this population.
Identifiants
pubmed: 37389726
doi: 10.1007/s13318-023-00841-9
pii: 10.1007/s13318-023-00841-9
doi:
Substances chimiques
Acetaminophen
362O9ITL9D
Glucuronides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
531-540Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Sridharan K, Hasan H, Al Jufairi M, Al Daylami A, Abdul Azeez Pasha S, Al Ansari E. Drug utilisation in adult, paediatric and neonatal intensive care units, with an emphasis on systemic antimicrobials. Anaesthesiol Intensive Ther. 2021; 53(1): 18-24.
Smith BS, Yogaratnam D, Levasseur-Franklin KE, Forni A, Fong J. Introduction to drug pharmacokinetics in the critically iII patient. Chest. 2012;141:1327–36.
doi: 10.1378/chest.11-1396
pubmed: 22553267
Tansley G, Hall R. Pharmacokinetic considerations for drugs administered in the critically ill. Br J Hosp Med. 2015;76:89–94.
doi: 10.12968/hmed.2015.76.2.89
Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient–concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3–11.
doi: 10.1016/j.addr.2014.07.006
pubmed: 25038549
Sridharan K, Pasha SAA, Qader AM, Hasan HMSN, El Seirafi MM. Drug Utilization in critically Ill adults with augmented renal clearance compared to normal renal clearance: implications for use of antimicrobials with predominant renal excretion. Curr Rev Clin Exp Pharmacol. 2021;16(2):174–81.
doi: 10.2174/1574884715666200810095225
pubmed: 32778038
Freo U, Ruocco C, Valerio A, Scagnol I, Nisoli E. Paracetamol: a review of guideline recommendations. J Clin Med. 2021;10:3420.
doi: 10.3390/jcm10153420
pubmed: 34362203
pmcid: 8347233
White PF. Cost-effective multimodal analgesia in the perioperative period: Use of intravenous vs. oral acetaminophen. J Clin Anesth. 2020; 61: 109625.
Morse JD, Stanescu I, Atkinson HC, Anderson BJ. Population pharmacokinetic modelling of acetaminophen and ibuprofen: the influence of body composition, formulation and feeding in healthy adult volunteers. Eur J Drug Metab Pharmacokinet. 2022. https://doi.org/10.1007/s13318-022-00766-9 .
doi: 10.1007/s13318-022-00766-9
pubmed: 35366213
pmcid: 9232434
Samson AD, Hunfeld NG, Touw DJ, Melief PH. Efficacy and pharmacokinetics of intravenous paracetamol in the critically ill patient. Crit Care. 2009;13(Suppl 1):P407.
doi: 10.1186/cc7571
pmcid: 4084293
Parker SL, Saxena M, Gowardman J, Lipman J, Myburgh J, Roberts JA. Population pharmacokinetics of intravenous paracetamol in critically ill patients with traumatic brain injury. J Crit Care. 2018;47:15–20.
doi: 10.1016/j.jcrc.2018.05.016
pubmed: 29883885
Geronimo-Pardo M, Fuster-Lluch O, Peyro-Garcia R, Lizan-Garcia M. Paracetamol pharmacokinetics in critically ill trauma patients. Eur J Anaesthesiol. 2010;27:153.
doi: 10.1097/00003643-201006121-00488
Athersuch TJ, Antoine DJ, Boobis AR, Coen M, Daly AK, Possamai L, Nicholson JK, Wilson ID. Paracetamol metabolism, hepatotoxicity, biomarkers and therapeutic interventions: a perspective. Toxicol Res (Camb). 2018;7(3):347–57.
doi: 10.1039/c7tx00340d
pubmed: 30090586
pmcid: 6062253
Horvatits T, Drolz A, Trauner M, Fuhrmann V. Liver injury and failure in critical illness. Hepatology. 2019;70(6):2204–15.
doi: 10.1002/hep.30824
pubmed: 31215660
Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol. 2010;5(6):1003–9.
doi: 10.2215/CJN.06870909
pubmed: 20299365
pmcid: 2879308
Chen IH, Nicolau DP. Augmented renal clearance and how to augment antibiotic dosing. Antibiotics (Basel). 2020;9(7):393.
doi: 10.3390/antibiotics9070393
pubmed: 32659898
pmcid: 7399877
Oscier CD, Milner QJ. Peri-operative use of paracetamol. Anaesthesia. 2009;64(1):65–72.
doi: 10.1111/j.1365-2044.2008.05674.x
pubmed: 19087009
Sridharan K, Qader AM, Hammad M, Jassim A, Diab DE, Abraham B, Hasan HMSN, Pasha SAA, Shah S. Evaluation of the association between single nucleotide polymorphisms of metabolizing enzymes with the serum concentration of paracetamol and its metabolites. Metabolites. 2022;12(12):1235.
doi: 10.3390/metabo12121235
pubmed: 36557273
pmcid: 9785892
Diab DE, Sridharan K. Development of urinary assay methods for the estimation of paracetamol glucuronide and paracetamol sulfate in preterm neonates with patent ductus arteriosus. Curr Chromat. 2022;9:1–5.
doi: 10.2174/2213240608666211202092036
Monolix version 2021R2. Antony, France: Lixoft SAS, 2022. http://lixoft.com/products/monolix/ . Accessed 9 October 2022.
Package ‘Rsmlx’. https://cran.r-project.org/web/packages/Rsmlx/Rsmlx.pdf . Accessed 9 Oct 2022.
Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol. 2002;40(1):3–20.
doi: 10.1081/CLT-120002882
pubmed: 11990202
Rawlins MD, Henderson DB, Hijab AR. Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. Eur J Clin Pharmacol. 1977;11(4):283–6.
doi: 10.1007/BF00607678
pubmed: 862649
Acetaminophen injection. Product monograph. Baxter corporation. https://www.baxter.ca/sites/g/files/ebysai1431/files/2021-08/EN_ACETAMINOPHEN%20INJECTION.pdf . Accessed 13 Oct 2022.
Allegaert K, Olkkola KT, Owens KH, Van de Velde M, de Maat MM, Anderson BJ; PACIA study group. Covariates of intravenous paracetamol pharmacokinetics in adults. BMC Anesthesiol 2014; 14: 77.
de Maat MM, Tijssen TA, Brüggemann RJ, Ponssen HH. Paracetamol for intravenous use in medium–and intensive care patients: pharmacokinetics and tolerance. Eur J Clin Pharmacol. 2010;66(7):713–9.
doi: 10.1007/s00228-010-0806-5
pubmed: 20300741
Kluge M, Tacke F. Liver impairment in critical illness and sepsis: the dawn of new biomarkers? Ann Transl Med. 2019;7(Suppl 8):S258.
doi: 10.21037/atm.2019.12.79
pubmed: 32015977
pmcid: 6976419